The Ozempic Effect
It happened again during the Medtronic the now standard question on how GLP-1 therapies such as Ozempic and Mounjaro are impacting the diabetes tech market. Geoff Martha CEO gave a pretty good answer basically saying there is no impact in Type 1 diabetes. Which is 100% accurate but that hasn’t changed the widely held perception that these therapies will crush diabetes tech companies.
Pure diabetes tech companies have seen their shares hammered as the belief is it won’t be long before EVERY person with diabetes is using these drugs and there will be no need for . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.